Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Download
Standard view
Full view
of .
Look up keyword
Like this
4Activity
0 of .
Results for:
No results containing your search query
P. 1
Ritonavir - Patent Landscape Report

Ritonavir - Patent Landscape Report

Ratings: (0)|Views: 423|Likes:
Ritonavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. It is included in the WHO Model List of Essential Medicines (EML). The originator company is Abbott Laboratories,
which markets Ritonavir under the brand name Norvir, or in combination with the protease
inhibitor Lopinavir, as Kaletra or Aluvia. The U.S. Food and Drug Administration (FDA)
approved the drug in March 1996 for oral solution and in June 1999 for capsules. Abbot
later received FDA and European Medicines Agency (EMEA) approval in 2010 for a heatstable
formulation of a 100mg Ritonavir tablet. This has particular importance for developing
countries with elevated ambient temperatures.
A major goal of this project is to highlight the technology timeline for Ritonavir from the first
filing of this compound in December 1993 by Abbott Laboratories (WO1994014436) to the
present filings in which additional patent families attempt to protect subsequent innovations
to the compound, variants and derivatives, combinations with other chemicals, methods of
production, methods of use, etc. The identification and analysis of these patent documents
showed that filings related to Ritonavir have increased dramatically since the initial disclosure
and now include over 800 patent families. A patent family is a collection of interrelated
patents that often contain the same disclosure and are typically related through dependence
on a common priority document or documents. On average, 45% of the patent families identified
during this patent landscape include at least one grant of a patent in one jurisdiction and thereby directly protect the various aspects of Ritonavir mentioned above.
Ritonavir is an antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS. It is included in the WHO Model List of Essential Medicines (EML). The originator company is Abbott Laboratories,
which markets Ritonavir under the brand name Norvir, or in combination with the protease
inhibitor Lopinavir, as Kaletra or Aluvia. The U.S. Food and Drug Administration (FDA)
approved the drug in March 1996 for oral solution and in June 1999 for capsules. Abbot
later received FDA and European Medicines Agency (EMEA) approval in 2010 for a heatstable
formulation of a 100mg Ritonavir tablet. This has particular importance for developing
countries with elevated ambient temperatures.
A major goal of this project is to highlight the technology timeline for Ritonavir from the first
filing of this compound in December 1993 by Abbott Laboratories (WO1994014436) to the
present filings in which additional patent families attempt to protect subsequent innovations
to the compound, variants and derivatives, combinations with other chemicals, methods of
production, methods of use, etc. The identification and analysis of these patent documents
showed that filings related to Ritonavir have increased dramatically since the initial disclosure
and now include over 800 patent families. A patent family is a collection of interrelated
patents that often contain the same disclosure and are typically related through dependence
on a common priority document or documents. On average, 45% of the patent families identified
during this patent landscape include at least one grant of a patent in one jurisdiction and thereby directly protect the various aspects of Ritonavir mentioned above.

More info:

Categories:Types, Business/Law
Copyright:Attribution Non-commercial

Availability:

Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less

03/15/2013

pdf

text

original

 
Patent Landscape Report on
Ritonavir 
OCTOBER 2011PATENTLANDSCAPEREPORTSPROJECT
 
 
The WIPO patent landscape report projectis based on the Development Agenda pro- ject DA_19_30_31_01 (“Developing Tools for  Access to Patent Information”) described indocument CDIP/4/6, adopted by the Com-mittee on Development and IntellectualProperty (CDIP) at its fourth session heldfrom November 16 to November 20, 2009.The purpose of each report is three-fold:- It attempts to research and describe thepatterns of patenting and innovation activityrelated to specific technologies in variousdomains such as health, food and agricul-ture, climate change related technologies,and others.- WIPO attempts to collaborate for each re-port with institutional partners (IGOs,NGOs, public institutions) working in therespective field and having an interest in aspecific topic. The collaborative work in theplanning and evaluation phase may alsoserve as a vehicle for these institutions tofamiliarize themselves with the utilizationand exploitation of patent information andrelated issues of patent protection. WIPOwelcomes proposals for collaboration.- Each report also serves as an illustrativeexample for retrieving patent information inthe respective field and how search strate-gies may be tailored accordingly. It there-fore includes detailed explanations of theparticular search methodology, the data-bases used and well documented searchqueries that should ideally enable thereader to conduct a similar search.Each report of this project is contracted outto an external firm selected in a tenderingprocedure. The tender is open to a limitednumber of bidders that were preselectedbased on their submission of an Expressionof Interest (EOI). WIPO invites the submis-sion of further EOIs by qualified providers.More information on the project, the ongo-ing work, and a compilation of reports pub-lished also by other institutions is availableat: www.wipo.int/patentscope/en/programs/patent_landscapes/pl_about.htmlFor specific information, requests or pro-posals, please contact us(patent.information@wipo.int)
 
 
Patent Landscape Report on
Ritonavir
Prepared for:World Intellectual Property OrganizationPrepared by:
Landon IPOctober 28, 2011

Activity (4)

You've already reviewed this. Edit your review.
1 thousand reads
1 hundred reads
Sunil Yadav liked this
12_schmitt6773 liked this

You're Reading a Free Preview

Download
scribd